Novel treatment of acute and acute-on-chronic liver failure: Interleukin-22

被引：11

作者：

Hwang, Seonghwan ^{[1
,2
]}

Hicks, Amy ^{[3
]}

Hoo, Chai Zhen ^{[3
]}

Kwon, Yong Seong ^{[1
,2
]}

Cho, Ye Eun ^{[1
,2
]}

Moore, Joanna ^{[3
]}

Gao, Bin ^{[4
]}

机构：

[1] Pusan Natl Univ, Res Inst Drug Dev, Coll Pharm, Busan 46241, South Korea

[2] Pusan Natl Univ, Res Inst Drug Dev, 63-2 Busandaehak Ro, Busan 46241, South Korea

[3] St James Univ Hosp, Leeds Liver Unit, Leeds, England

[4] NIAAA, Lab Liver Dis, NIH, Bethesda, MD USA

来源：

LIVER INTERNATIONAL | 2025年 / 45卷 / 03期

基金：

新加坡国家研究基金会;

关键词：

acute liver failure; acute-on-chronic liver failure; interleukin-22; EARLY-STAGE; HEPATITIS; IL-22; ACETAMINOPHEN; DISEASE; INJURY; INFLAMMATION; CONCANAVALIN; CELLS; MICE;

D O I：

10.1111/liv.15619

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Acute liver failure (ALF) is a life-threatening medical condition, characterized by rapidly progressive hepatic dysfunction, coagulopathy and hepatic encephalopathy in patients without chronic liver disease, while acute-on-chronic liver failure (ACLF) occurs in patients with existing chronic liver disease. ALF and ACLF are often associated with multiple organ failure and a high short-term mortality. In this review, we briefly discuss the causes and pathogenesis of ALF and ACLF, the current options available for the treatment of both deadly maladies and interleukin-22 (IL-22), a novel promising drug that may have great therapeutic potential for ALF and ACLF treatment. IL-22 is a cytokine produced by immune cells but mainly targets epithelial cells including hepatocytes. IL-22 has been shown to protect against organ damage and reduce bacterial infection in many preclinical models and several clinical trials including alcohol-associated hepatitis. The potential application of IL-22 for the treatment of ALF and ACLF is also elaborated.

引用

页数：9

共 80 条

[1]

Akamatsu N, 2013, INTRACTABLE RARE DIS, V2, P77, DOI 10.5582/irdr.2013.v2.3.77

[2] Clinical and economic characteristics of emergency department visits due to acetaminophen toxicity in the USA [J].